Chairman Rick Scott, Ranking Member Gillibrand Send Letter to FDA Commissioner Ahead of Aging Hearing on Rare Disease Treatment Authorization

WASHINGTON, D.C. - Today, Chairman Rick Scott and Ranking Member Kirsten Gillibrand of the U.S. Senate Special Committee on Aging sent a letter to the Food and Drug Administration (FDA) Commissioner Dr. Martin Makary announcing that the committee will be convening a hearing to examine the FDA's treatment authorization process for rare diseases. The upcoming hearing will focus on the rare disease drug development pipeline, assess regulatory barriers, and explore how the FDA can better support innovation while maintaining the highest standards of safety and scientific integrity.

In their letter, Chairman Scott and Ranking Member Gillibrand emphasize that more than 30 million Americans are affected by rare diseases, the vast majority of which have no approved therapies, and asked the commissioner to outline the FDA's efforts to find solutions as they work together to turn hope into reality for these patients and their families.

Read the full letter HERE or below:

###